Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies

Haematologica. 2024 Jan 25. doi: 10.3324/haematol.2023.283861. Online ahead of print.

¹ BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA. Linlin.Xu@beigene.com.
² Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA.
³ Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.
⁴ Texas Oncology Baylor Charles A. Sammons Cancer Center, Dallas, TX.
⁵ SSM Health Dean Medical Group, Madison, WI.
⁶ Rocky Mountain Cancer Centers, Aurora, CO.
⁷ Florida Cancer Specialists and Research Institute, Fort Myers, FL.
⁸ Florida Cancer Specialists and Research Institute, Leesburg, FL.
⁹ Medical Oncology Hematology Consultants PA, Newark, DE.
¹⁰ Comprehensive Cancer Centers of Nevada, Las Vegas, NV.
¹¹ Texas Oncology, Tyler, TX.
¹² Summit Medical Group, Florham Park, NJ.
¹³ Summit Cancer Centers, Spokane, WA.
¹⁴ Texas Oncology, Amarillo, TX.
¹⁵ Virginia Cancer Specialists, Gainesville, VA.
¹⁶ BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA.
¹⁷ Arizona Oncology / US Oncology Research, Tucson, AZ, USA; and.
¹⁸ Willamette Valley Cancer Institute and Research Center, Eugene, OR.

Abstract

Not available.